Trial Profile
A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies (CAMELLIA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Magrolimab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms CAMELLIA
- Sponsors Gilead Sciences
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Jul 2018 Planned End Date changed from 1 Aug 2018 to 1 Jan 2019.
- 31 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.